{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T02:24:00Z","timestamp":1794191040483,"version":"4.8.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s10637-026-01625-z","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T01:31:49Z","timestamp":1784770309000},"page":"401-413","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Novel EGFR tyrosine kinase inhibitors exhibiting intrinsic fluorescence"],"prefix":"10.1007","volume":"44","author":[{"given":"Amelia","family":"Kierasi\u0144ska-Ka\u0142ka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrianna","family":"Rutkowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Mularski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Pacholczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadeusz","family":"Str\u00f3zik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"P\u0119ciak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cezary","family":"Tr\u0119da","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaudia","family":"Waszczykowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Orlikowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominika","family":"Wyrzykowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamil","family":"Filiks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Jask\u00f3lska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Bartkowiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewelina","family":"Stoczy\u0144ska-Fidelus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Rieske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"1625_CR1","first-page":"3217","volume":"53","author":"IE Garcia de Palazzo","year":"1993","unstructured":"Garcia de Palazzo IE, Adams GP, Sundareshan P et al (1993) Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas. Cancer Res 53:3217\u20133220","journal-title":"Cancer Res"},{"issue":"23","key":"1625_CR2","first-page":"5536","volume":"55","author":"DK Moscatello","year":"1995","unstructured":"Moscatello DK, Holgado-Madruga M, Godwin AK et al (1995) Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res 55(23):5536\u20135539","journal-title":"Cancer Res"},{"key":"1625_CR3","doi-asserted-by":"publisher","first-page":"146","DOI":"10.7150\/JCA.16108","volume":"8","author":"J Peciak","year":"2017","unstructured":"Peciak J, Stec WJ, Treda C et al (2017) Low incidence along with low mRNA levels of EGFRvIII in prostate and colorectal cancers compared to glioblastoma. J Cancer 8:146\u2013151. https:\/\/doi.org\/10.7150\/JCA.16108","journal-title":"J Cancer"},{"key":"1625_CR4","doi-asserted-by":"publisher","first-page":"7181368","DOI":"10.1155\/2018\/7181368","volume":"2018","author":"M Peng","year":"2018","unstructured":"Peng M, Weng YM, Liu HL et al (2018) Clinical characteristics and survival outcomes for non-small-cell lung cancer patients with epidermal growth factor receptor double mutations. BioMed Res Int 2018:7181368. https:\/\/doi.org\/10.1155\/2018\/7181368","journal-title":"BioMed Res Int"},{"key":"1625_CR5","doi-asserted-by":"publisher","first-page":"31907","DOI":"10.18632\/oncotarget.8201","volume":"7","author":"WJ Stec","year":"2016","unstructured":"Stec WJ, Rosiak K, Siejka P et al (2016) Cell line with endogenous EGFRvIII expression is a suitable model for research and drug development purposes. Oncotarget 7:31907\u201331925. https:\/\/doi.org\/10.18632\/oncotarget.8201","journal-title":"Oncotarget"},{"key":"1625_CR6","doi-asserted-by":"publisher","first-page":"6968","DOI":"10.1038\/sj.onc.1210503","volume":"26","author":"K Shtiegman","year":"2007","unstructured":"Shtiegman K, Kochupurakkal BS, Zwang Y et al (2007) Defective ubiquitinylation of EGFR mutants of lung cancer confers prolonged signaling. Oncogene 26:6968\u20136978. https:\/\/doi.org\/10.1038\/sj.onc.1210503","journal-title":"Oncogene"},{"issue":"21","key":"1625_CR7","first-page":"5079","volume":"56","author":"M Nagane","year":"1996","unstructured":"Nagane M, Coufal F, Lin H et al (1996) A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res 56(21):5079\u20135086","journal-title":"Cancer Res"},{"key":"1625_CR8","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1016\/j.biopha.2018.09.151","volume":"109","author":"R Ni","year":"2019","unstructured":"Ni R, Huang Y, Wang J, Liu Y (2019) Knockdown of lncRNA DLX6-AS1 inhibits cell proliferation, migration and invasion while promotes apoptosis by downregulating PRR11 expression and upregulating miR-144 in non-small cell lung cancer. Biomed Pharmacother 109:1851\u20131859. https:\/\/doi.org\/10.1016\/j.biopha.2018.09.151","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"1625_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0155230","volume":"11","author":"C Treda","year":"2016","unstructured":"Treda C, Popeda M, Ksiazkiewicz M et al (2016) EGFR activation leads to cell death independent of PI3K\/AKT\/mTOR in an AD293 cell line. PLoS One 11(5):e0155230. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0155230","journal-title":"PLoS One"},{"key":"1625_CR10","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1124\/jpet.112.197756","volume":"343","author":"F Solca","year":"2012","unstructured":"Solca F, Dahl G, Zoephel A et al (2012) Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther 343:342\u2013350. https:\/\/doi.org\/10.1124\/jpet.112.197756","journal-title":"J Pharmacol Exp Ther"},{"key":"1625_CR11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/1087057116671509","volume":"22","author":"JM Strelow","year":"2017","unstructured":"Strelow JM (2017) A perspective on the kinetics of covalent and irreversible inhibition. SLAS Discov 22:3\u201320. https:\/\/doi.org\/10.1177\/1087057116671509","journal-title":"SLAS Discov"},{"key":"1625_CR12","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jphotochem.2015.05.033","volume":"316","author":"TM Siclovan","year":"2016","unstructured":"Siclovan TM, Zhang R, Cotero V et al (2016) Fluorescence phenomena in nerve-labeling styryl-type dyes. J Photochem Photobiol A Chem 316:104\u2013116. https:\/\/doi.org\/10.1016\/j.jphotochem.2015.05.033","journal-title":"J Photochem Photobiol A Chem"},{"key":"1625_CR13","doi-asserted-by":"publisher","first-page":"7564","DOI":"10.1021\/jo501305h","volume":"79","author":"S Achelle","year":"2014","unstructured":"Achelle S, Rodr\u00edguez-L\u00f3pez J, Robin-Le Guen F (2014) Synthesis and photophysical studies of a series of quinazoline chromophores. J Org Chem 79:7564\u20137571. https:\/\/doi.org\/10.1021\/jo501305h","journal-title":"J Org Chem"},{"key":"1625_CR14","doi-asserted-by":"publisher","first-page":"4940","DOI":"10.1021\/jo500520x","volume":"79","author":"J Dhuguru","year":"2014","unstructured":"Dhuguru J, Liu W, Gonzalez WG et al (2014) Emission tuning of fluorescent kinase inhibitors: conjugation length and substituent effects. J Org Chem 79:4940\u20134947. https:\/\/doi.org\/10.1021\/jo500520x","journal-title":"J Org Chem"},{"key":"1625_CR15","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1039\/C5TC03933A","volume":"4","author":"S Sasaki","year":"2016","unstructured":"Sasaki S, Drummen GPC, Konishi GI (2016) Recent advances in twisted intramolecular charge transfer (TICT) fluorescence and related phenomena in materials chemistry. J Mater Chem C 4:2731\u20132743. https:\/\/doi.org\/10.1039\/C5TC03933A","journal-title":"J Mater Chem C"},{"key":"1625_CR16","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1038\/nbt1210-1248","volume":"28","author":"M Uhlen","year":"2010","unstructured":"Uhlen M, Oksvold P, Fagerberg L et al (2010) Towards a knowledge-based Human Protein Atlas. Nat Biotechnol 28:1248\u20131250. https:\/\/doi.org\/10.1038\/nbt1210-1248","journal-title":"Nat Biotechnol"},{"issue":"6220","key":"1625_CR17","doi-asserted-by":"publisher","DOI":"10.1126\/science.1260419","volume":"347","author":"M Uhl\u00e9n","year":"2015","unstructured":"Uhl\u00e9n M, Fagerberg L, Hallstr\u00f6m BM et al (2015) Tissue-based map of the human proteome. Science 347(6220):1260419. https:\/\/doi.org\/10.1126\/science.1260419","journal-title":"Science"},{"key":"1625_CR18","doi-asserted-by":"publisher","first-page":"5461","DOI":"10.2147\/OTT.S94745","volume":"9","author":"X Wang","year":"2016","unstructured":"Wang X, Goldstein D, Crowe PJ, Yang JL (2016) Next-generation EGFR\/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence. Onco Targets Ther 9:5461. https:\/\/doi.org\/10.2147\/OTT.S94745","journal-title":"Onco Targets Ther"},{"key":"1625_CR19","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1038\/S41388-017-0045-7","volume":"37","author":"Z An","year":"2018","unstructured":"An Z, Aksoy O, Zheng T et al (2018) Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies. Oncogene 37:1561\u20131575. https:\/\/doi.org\/10.1038\/S41388-017-0045-7","journal-title":"Oncogene"},{"key":"1625_CR20","doi-asserted-by":"publisher","first-page":"5006","DOI":"10.1039\/c5ob00239g","volume":"13","author":"JN Wilson","year":"2015","unstructured":"Wilson JN, Liu W, Brown AS, Landgraf R (2015) Binding-induced, turn-on fluorescence of the EGFR\/ERBB kinase inhibitor, lapatinib. Org Biomol Chem 13:5006\u20135011. https:\/\/doi.org\/10.1039\/c5ob00239g","journal-title":"Org Biomol Chem"},{"key":"1625_CR21","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1007\/s10637-020-00958-7","volume":"39","author":"N Golabi","year":"2021","unstructured":"Golabi N, Larroque AL, Peyrard L et al (2021) Subcellular distribution and mechanism of action of AL906, a novel and potent EGFR inhibitor rationally designed to be green fluorescent. Invest New Drugs 39:240\u2013250. https:\/\/doi.org\/10.1007\/s10637-020-00958-7","journal-title":"Invest New Drugs"},{"issue":"6944","key":"1625_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/S41467-022-34627-5","volume":"13","author":"H Deng","year":"2022","unstructured":"Deng H, Lei Q, Wang C et al (2022) A fluorogenic probe for predicting treatment response in non-small cell lung cancer with EGFR-activating mutations. Nat Commun 13(6944):1\u201319. https:\/\/doi.org\/10.1038\/S41467-022-34627-5","journal-title":"Nat Commun"},{"key":"1625_CR23","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/jmr.581","volume":"15","author":"LF Pineda De Castro","year":"2002","unstructured":"Pineda De Castro LF, Zacharias M (2002) DAPI binding to the DNA minor groove: a continuum solvent analysis. J Mol Recognit 15:209\u2013220. https:\/\/doi.org\/10.1002\/jmr.581","journal-title":"J Mol Recognit"},{"key":"1625_CR24","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jcyt.2012.07.001","volume":"15","author":"A Aldridge","year":"2013","unstructured":"Aldridge A, Kouroupis D, Churchman S et al (2013) Assay validation for the assessment of adipogenesis of multipotential stromal cells-a direct comparison of four different methods. Cytotherapy 15:89\u2013101. https:\/\/doi.org\/10.1016\/j.jcyt.2012.07.001","journal-title":"Cytotherapy"},{"key":"1625_CR25","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/978-1-4939-1050-2_3","volume":"1180","author":"AT Feldman","year":"2014","unstructured":"Feldman AT, Wolfe D (2014) Tissue processing and hematoxylin and eosin staining. Methods Mol Biol 1180:31\u201343. https:\/\/doi.org\/10.1007\/978-1-4939-1050-2_3","journal-title":"Methods Mol Biol"},{"key":"1625_CR26","doi-asserted-by":"publisher","first-page":"14054","DOI":"10.1021\/bi961047t","volume":"35","author":"EM De La Cruz","year":"1996","unstructured":"De La Cruz EM, Pollard TD (1996) Kinetics and thermodynamics of phalloidin binding to actin filaments from three divergent species. Biochemistry 35:14054\u201314061. https:\/\/doi.org\/10.1021\/bi961047t","journal-title":"Biochemistry"},{"issue":"5","key":"1625_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS24054350","volume":"24","author":"C Tr\u0119da","year":"2023","unstructured":"Tr\u0119da C, W\u0142odarczyk A, Pacholczyk M et al (2023) Increased EGFRvIII epitope accessibility after tyrosine kinase inhibitor treatment of glioblastoma cells creates more opportunities for immunotherapy. Int J Mol Sci 24(5):4350. https:\/\/doi.org\/10.3390\/IJMS24054350","journal-title":"Int J Mol Sci"},{"key":"1625_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s42004-025-01501-6","volume":"8","author":"PA Morese","year":"2025","unstructured":"Morese PA, Ahmad A, Martin MP et al (2025) Factors affecting irreversible inhibition of EGFR and influence of chirality on covalent binding. Commun Chem 8:111. https:\/\/doi.org\/10.1038\/s42004-025-01501-6","journal-title":"Commun Chem"},{"key":"1625_CR29","doi-asserted-by":"publisher","unstructured":"Smith S, Keul M, Engel J et al (2017) Characterization of covalent-reversible EGFR inhibitors. ACS Omega 2:1563\u20131575. https:\/\/doi.org\/10.1021\/acsomega.7b00157","DOI":"10.1021\/acsomega.7b00157"},{"key":"1625_CR30","doi-asserted-by":"publisher","unstructured":"Schwartz PA, Kuzmic P, Solowiej J et al (2014) Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance. Proc Natl Acad Sci U S A 111:173\u2013178. https:\/\/doi.org\/10.1073\/pnas.1313733111","DOI":"10.1073\/pnas.1313733111"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-026-01625-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-026-01625-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-026-01625-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T02:08:50Z","timestamp":1794190130000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-026-01625-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["1625"],"URL":"https:\/\/doi.org\/10.1007\/s10637-026-01625-z","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]},"assertion":[{"value":"1 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable. This study did not involve human participants, human tissue samples, animal experiments, or clinical data.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}